Literature DB >> 15106954

Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe.

Joseph Frucht-Pery1, Hadas Mechoulam, Charalambos S Siganos, Pnina Ever-Hadani, Mervyn Shapiro, Abraham Domb.   

Abstract

PURPOSE: To evaluate the efficacy of penetration of gentamicin into the cornea of rabbits using iontophoresis with a hydrogel-gentamicin containing probe.
METHODS: Eight of 10 groups (groups 3-10) of 6 rabbits (one eye per rabbit), underwent corneal iontophoresis using soft stable hydroxyethyl methacrylate hydrogel discs (80% water content) loaded with gentamicin sulphate which were mounted on an iontophoresis probe. The studied current intensities were 0, 0.1, 0.3 and 0.6 mAmp, and the durations of iontophoresis were 10 and 60 sec. Two control groups received 1.4% topical drops of gentamicin every 5 min for 1 hr (group 1) or sub-conjunctival injection of 10 mg gentamicin (group 2). Following sacrifice, aqueous humour was taken, corneas were excised, and gentamicin concentration was determined in aqueous humour and cornea samples.
RESULTS: Post-iontophoresis, the concentration of gentamicin in the corneas ranged from high (88.60 +/- 38.64 microg ml(-1)) to very low (0.10 +/- 0.89 microg ml(-1)). Both the control groups and those rabbits treated with current intensity of 0.1 mAmp or greater obtained therapeutic gentamicin levels in the corneas. Use of iontophoresis for 60 sec or current intensity greater than 0.1 mAmp obtained corneal gentamicin levels not different from sub-conjunctival injection. Application of current intensity of 0.1 mAmp or greater gave corneal gentamicin concentrations comparable to topical application of the drug, except when 0.6 mAmp were used for 60 sec (p = 0.05). Increasing current intensity or duration of iontophoresis significantly increased (p = 0.001 for both) gentamicin penetration into the cornea. Current intensity had more influence (Beta2 = 0.40) than duration (Beta2 = 0.13) on drug penetration. A significant interaction was found between the duration of iontophoresis and the current intensity. Very small or no concentrations of the drug were discovered in the anterior chambers of rabbits.
CONCLUSIONS: Iontophoresis using hydrogel-gentamicin probe may deliver therapeutic concentrations of gentamicin into the cornea.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106954     DOI: 10.1016/s0014-4835(03)00215-x

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

Review 1.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

2.  A flexible device for ocular iontophoretic drug delivery.

Authors:  Yushi Zhang; Yao Chen; Xiaoxue Yu; Yangjia Qi; Yufeng Chen; Yuxi Liu; Yuntao Hu; Zhihong Li
Journal:  Biomicrofluidics       Date:  2016-02-24       Impact factor: 2.800

3.  Dual-Phase Iontophoresis for the Delivery of Antisense Oligonucleotides.

Authors:  Daniel J Gibson; Sonal S Tuli; Gregory S Schultz
Journal:  Nucleic Acid Ther       Date:  2017-04-04       Impact factor: 5.486

4.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

5.  Niosome-encapsulated gentamicin for ophthalmic controlled delivery.

Authors:  Ghada Abdelbary; Nashwa El-Gendy
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

6.  Standard corneal collagen crosslinking versus transepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: randomized control trial.

Authors:  Guzel Bikbova; Mukharram Bikbov
Journal:  Acta Ophthalmol       Date:  2016-04-04       Impact factor: 3.761

Review 7.  Selected Medicines Used in Iontophoresis.

Authors:  Tomasz M Karpiński
Journal:  Pharmaceutics       Date:  2018-10-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.